The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
This is used to treat central diabetes insipidus and bedwetting
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
ALS patients experience neuroinflammation and rapid neurodegeneration
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Subscribe To Our Newsletter & Stay Updated
